|Appears in Collections:||Biological and Environmental Sciences Journal Articles|
|Peer Review Status:||Refereed|
|Title:||p53 loss in Myc-driven neuroblastoma leads to metabolic adaptations supporting radioresistance|
Almeida, Gilberto S
Smith, Laura M
Raynaud, Florence I
Robinson, Simon P
Keun, Hector C
|Citation:||Yogev O, Barker K, Sikka A, Almeida GS, Hallsworth A, Smith LM, Jamin Y, Ruddle R, Koers A, Webber H, Raynaud FI, Popov S, Jones C, Petrie K, Robinson SP, Keun HC & Chesler L (2016) p53 loss in Myc-driven neuroblastoma leads to metabolic adaptations supporting radioresistance, Cancer Research, 76 (10), pp. 3025-3035.|
|Abstract:||Neuroblastoma is the most common childhood extracranial solid tumor. In high-risk cases, many of which are characterized by amplification ofMYCN, outcome remains poor. Mutations in the p53 (TP53) tumor suppressor are rare at diagnosis, but evidence suggests that p53 function is often impaired in relapsed, treatment-resistant disease. To address the role of p53 loss of function in the development and pathogenesis of high-risk neuroblastoma, we generated a MYCN-driven genetically engineered mouse model in which the tamoxifen-inducible p53ERTAMfusion protein was expressed from a knock-in allele (Th-MYCN/Trp53KI). We observed no significant differences in tumor-free survival between Th-MYCNmice heterozygous forTrp53KI(n= 188) and Th-MYCNmice with wild-type p53 (n= 101). Conversely, the survival of Th-MYCN/Trp53KI/KImice lacking functional p53 (n= 60) was greatly reduced. We found that Th-MYCN/Trp53KI/KItumors were resistant to ionizing radiation (IR), as expected. However, restoration of functional p53ERTAMreinstated sensitivity to IR in only 50% of Th-MYCN/Trp53KI/KItumors, indicating the acquisition of additional resistance mechanisms. Gene expression and metabolic analyses indicated that the principal acquired mechanism of resistance to IR in the absence of functional p53 was metabolic adaptation in response to chronic oxidative stress. Tumors exhibited increased antioxidant metabolites and upregulation of glutathione S-transferase pathway genes, includingGstp1andGstz1, which are associated with poor outcome in human neuroblastoma. Accordingly, glutathione depletion by buthionine sulfoximine together with restoration of p53 activity resensitized tumors to IR. Our findings highlight the complex pathways operating in relapsed neuroblastomas and the need for combination therapies that target the diverse resistance mechanisms at play.|
|Rights:||The publisher does not allow this work to be made publicly available in this Repository. Please use the Request a Copy feature at the foot of the Repository record to request a copy directly from the author. You can only request a copy if you wish to use this work for your own research or private study.|
|Cancer Res-2016-Yogev-3025-35.pdf||2.44 MB||Adobe PDF||Under Permanent Embargo Request a copy|
Note: If any of the files in this item are currently embargoed, you can request a copy directly from the author by clicking the padlock icon above. However, this facility is dependent on the depositor still being contactable at their original email address.
This item is protected by original copyright
Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
If you believe that any material held in STORRE infringes copyright, please contact email@example.com providing details and we will remove the Work from public display in STORRE and investigate your claim.